Table of Contents
ISRN Gastroenterology
Volume 2011, Article ID 672017, 3 pages
Clinical Study

The Reasons for Discontinuation of Infliximab Treatment in Patients with Crohn's Disease: A Review of Practice at NHS Teaching Hospital

1Gastroenterology Department, Norfolk and Norwich University Hospital NHS Trust, Norwich NR4 7UY, UK
2School of Medicine, Health Policy and Practice, University of East Anglia, Norwich NR4 7TJ, UK

Received 18 July 2011; Accepted 1 September 2011

Academic Editors: W. A. Meier-Ruge, A. Nakajima, and W. Vogel

Copyright © 2011 Lukasz Z. Krupa et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. M. Reimund, C. Wittersheim, S. Dumont et al., “Increased production of tumour necrosis factor-α, interleukin-1β, and interleukin-6 by morphologically normal intestinal biopsies from patients with Crohn's disease,” Gut, vol. 39, no. 5, pp. 684–689, 1996. View at Google Scholar · View at Scopus
  2. S. B. Hanauer, B. G. Feagan, G. R. Lichtenstein et al., “Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial,” Lancet, vol. 359, no. 9317, pp. 1541–1549, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. S. R. Targan, S. B. Hanauer, S. J. H. Van Deventer et al., “A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's Disease,” New England Journal of Medicine, vol. 337, no. 15, pp. 1029–1035, 1997. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. F. Schnitzler, H. Fidder, M. Ferrante et al., “Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort,” Gut, vol. 58, no. 4, pp. 492–500, 2009. View at Publisher · View at Google Scholar · View at PubMed
  5. NICE- 2010, “Final appraisal determination: Crohn's disease - infliximab (review) and adalimumab”.